Medication-related osteonecrosis of the jaw (ONJ) is an adverse event (AE) of antiresorptive treatments, firstly reported with the use of bisphosphonates. It is defined as an area of exposed bone or bone that can be probed through an intraoral or extraoral fistula in the maxillofacial region, that persisted for more than eight weeks in patients exposed to these drugs [
]. The pathophysiology is multifactorial, being correlated with the dose and duration of exposure to antiresorptive drugs as well as the type, pre-existing dental disease, poor oral hygiene, and oral surgery immediately preceding or during treatment with antiresorptive agents [
- Ruggiero S.L.
- Dodson T.B.
- Fantasia J.
- Goodday R.
- Aghaloo T.
- Mehrotra B.
- et al.
American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw—2014 update.
J Oral Maxillofac Surg. 2014; 72: 1938-1956https://doi.org/10.1016/j.joms.2014.04.031
- Khan A.A.
- Morrison A.
- Hanley D.A.
- Felsenberg D.
- McCauley L.K.
- O'Ryan F.
- et al.
Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus.
J Bone Miner Res. 2015; 30: 3-23https://doi.org/10.1002/jbmr.2405
- Anastasilakis A.D.
- Pepe J.
- Napoli N.
- Palermo A.
- Magopoulos C.
- Khan A.A.
- et al.
Osteonecrosis of the jaw and antiresorptive agents in benign and malignant diseases: a critical review organized by ECTS.
J Clin Endocrinol Metabol. 2021; dgab888https://doi.org/10.1210/clinem/dgab888
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Cancer
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw—2014 update.J Oral Maxillofac Surg. 2014; 72: 1938-1956https://doi.org/10.1016/j.joms.2014.04.031
- Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus.J Bone Miner Res. 2015; 30: 3-23https://doi.org/10.1002/jbmr.2405
- Osteonecrosis of the jaw and antiresorptive agents in benign and malignant diseases: a critical review organized by ECTS.J Clin Endocrinol Metabol. 2021; dgab888https://doi.org/10.1210/clinem/dgab888
- CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaws.Dentomaxillofacial Radiol. 2018; : 20170323https://doi.org/10.1259/dmfr.20170323
- Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials.Clin Oral Implants Res. 2016; 27: 367-375https://doi.org/10.1111/clr.12556
- Osteonecrosis of the jaw after osteoporosis therapy with denosumab following long-term bisphosphonate therapy.Mayo Clin Proc. 2013; 88: 418-419https://doi.org/10.1016/j.mayocp.2013.01.002
- Denosumab-related osteonecrosis of the jaws.Osteoporos Int. 2011; 22: 369-370https://doi.org/10.1007/s00198-010-1177-6
- Antiresorptive drug-related changes of the mandibular bone density in medication-related osteonecrosis of the jaw patients.Dentomaxillofacial Radiol. 2019; 48: 20190132https://doi.org/10.1259/dmfr.20190132
- A comparison of the cone beam computed tomography findings in medication-related osteonecrosis of the jaws related to denosumab versus bisphosphonates: an observational pilot study.Oral Surg Oral Med Oral Pathol Oral Radiol. 2020; 129: 411-417https://doi.org/10.1016/j.oooo.2019.09.010
- Can dental panoramic radiographic findings serve as indicators for the development of medication-related osteonecrosis of the jaw?.Dentomaxillofacial Radiol. 2016; 45: 20160065https://doi.org/10.1259/dmfr.20160065
- Differences between bisphosphonate-related and denosumab-related osteonecrosis of the jaws: a systematic review.Support Care Cancer. 2021; 29: 2811-2820https://doi.org/10.1007/s00520-020-05855-6
- Early bony changes associated with bisphosphonate-related osteonecrosis of the jaws in rats: a longitudinal in vivo study.Arch Oral Biol. 2017; 82: 79-85https://doi.org/10.1016/j.archoralbio.2017.06.002
- Biomarkers to predict the onset of biphosphonate-related osteonecrosis of the jaw: a systematic review.Med Oral. 2018; : 0-0https://doi.org/10.4317/medoral.22763
Published online: March 08, 2022
Accepted: January 12, 2022
Received in revised form: January 4, 2022
Received: December 10, 2021
© 2022 Elsevier Ltd. All rights reserved.